newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for